E. Ohman J:Or Asset Management Ab Zai Lab LTD Transaction History

E. Ohman J:Or Asset Management Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 05, 2024	SELL	$25.3 - $39.67 $326,370 - $511,743	-12,900 Closed	0 $0
Q4 2022 Apr 05, 2024	BUY	$22.28 - $38.71 $49,016 - $85,162	2,200 Added 20.56%	12,900 $396 Million
Q2 2022 Apr 05, 2024	SELL	$23.14 - $49.68 $92,560 - $198,720	-4,000 Reduced 27.21%	10,700 $371 Million
Q2 2021 Apr 05, 2024	BUY	$125.11 - $180.0 $162,643 - $234,000	1,300 Added 9.7%	14,700 $2.6 Billion
Q1 2021 Apr 05, 2024	BUY	$126.27 - $191.71 $214,659 - $325,907	1,700 Added 14.53%	13,400 $1.79 Billion
Q4 2020 Apr 05, 2024	BUY	$81.94 - $135.34 $360,536 - $595,496	4,400 Added 60.27%	11,700 $1.58 Billion
Q2 2020 Apr 05, 2024	BUY	$48.82 - $82.53 $356,386 - $602,469	7,300 New	7,300 $600 Million

117

40.9M

63.1K

420K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.58B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.